Every company that fits your thesis, including the ones you’ve never heard of
Most target lists start wide and take several rounds with the business units to cut down. Klaro starts from your criteria, so the first list you see holds only the companies that fit, each with the reason it’s there.
.png){kind=logo}
Most deals are lost before diligence starts
By the time a company reaches a banker's teaser, every serious buyer is reading the same deck. The earlier signs were there for months, in a paper, a patent filing, a trial registry or a first funding round. Klaro reads all of them together.
Early signals. Papers, patents, clinical trials and first rounds, read side by side, so a target shows up while it still has no banker.
Banker-led flow. Teasers and auctions bring you the same companies, on the same timeline, as every other buyer in the process.
12 to 24 months. How much earlier buyers who catch those first signals start building the relationship with the founders.
More of what fits. Less of what doesn't.
Average results of a Deep Search across 10K+ spaces, compared with a legacy database.
≈ 63 hoursof analyst time per space goes into reviewing the 761 companies that don’t fit, at about five minutes each.
From thesis to Investment Committee in one place
Privately held companies in Europe with a diagnostic for antimicrobial resistance that's in trials or already on the market.
Example thesis, for illustration.
Example output. Company names hidden, counts illustrative.
Example output. Company names hidden.
Rapid susceptibility testing, privately held, Europe
- Thesis fit
- Diagnostic for antimicrobial resistance, in a registered trial
- Why now
- Trial registered this quarter; no institutional round since seed
- Evidence
- 3 patent families, 6 papers, 1 clinical trial, funding history
- Sources
- Linked for every line, so the Investment Committee can check them
Example output, for illustration.
Know when a target starts to move
Put your thesis and your shortlist on watch. Klaro reads new patents, papers, trials, funding rounds and filed accounts as they come in, and shows you which ones change the case for a deal.
- Phase 2 trial registeredTarget 11 · Antibody-drug conjugates
- New patent family filedTarget 04 · Oral peptide delivery
- Series B announcedTarget 02 · Embedded insurance
- Annual accounts filedTarget 09 · Industrial sensors
- New paper from the founding teamTarget 07 · Solid-state electrolytes
The way your team already works
Find the companies nobody is shopping
Patents, papers and trials sit next to company data, so targets surface before they have a banker, and sometimes before they've raised at all.
Lost one at auction? Find the next one
Start from a company you know and get the ones that look like it, with the reasons they match.
See the spaces next to your thesis
Klaro suggests adjacent spaces and whitespace you weren't looking at. That pays off most when the obvious names are already spoken for.
Size a target before the first call
Financials for 3.5M+ companies, so you know whether a privately held target is in range before anyone picks up the phone.
What changes when the longlist is complete
“Before, we spent a lot of time reviewing broad outputs. Now, with Klaro, we can immediately narrow down to the 20 or so companies that fit our strategy and track them closely.”
Less chance a target first reaches you as part of someone else's process.
From longlist to shortlist faster, with a rationale the Investment Committee can check.
Everything on a target, in one file
Target A Rapid susceptibility testing · privately held · Europe
- Comparable companiesMapped
- FinancialsRevenue range
- Patent familiesLinked
- PublicationsFounding team
- Clinical trialsRegistered
What's on your acquisition thesis?
Type it in and see who's in the space, including the companies that aren't on your list yet.
Prefer a walkthrough with our team? Book a demo